248 related articles for article (PubMed ID: 12370044)
1. Recent advances in topoisomerase I-targeting agents, camptothecin analogues.
Kim DK; Lee N
Mini Rev Med Chem; 2002 Dec; 2(6):611-9. PubMed ID: 12370044
[TBL] [Abstract][Full Text] [Related]
2. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
Lavergne O; Bigg DC
Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086
[TBL] [Abstract][Full Text] [Related]
3. Camptothecin and its analogues: a review on their chemotherapeutic potential.
Sriram D; Yogeeswari P; Thirumurugan R; Bal TR
Nat Prod Res; 2005 Jun; 19(4):393-412. PubMed ID: 15938148
[TBL] [Abstract][Full Text] [Related]
4. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I.
Champoux JJ
Ann N Y Acad Sci; 2000; 922():56-64. PubMed ID: 11193925
[TBL] [Abstract][Full Text] [Related]
5. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.
Takagi K; Dexheimer TS; Redon C; Sordet O; Agama K; Lavielle G; Pierré A; Bates SE; Pommier Y
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3229-38. PubMed ID: 18089716
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
7. Review camptothecin: current perspectives.
Li QY; Zu YG; Shi RZ; Yao LP
Curr Med Chem; 2006; 13(17):2021-39. PubMed ID: 16842195
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin.
Hautefaye P; Cimetière B; Pierré A; Léonce S; Hickman J; Laine W; Bailly C; Lavielle G
Bioorg Med Chem Lett; 2003 Aug; 13(16):2731-5. PubMed ID: 12873503
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
[TBL] [Abstract][Full Text] [Related]
10. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.
Lesueur-Ginot L; Demarquay D; Kiss R; Kasprzyk PG; Dassonneville L; Bailly C; Camara J; Lavergne O; Bigg DC
Cancer Res; 1999 Jun; 59(12):2939-43. PubMed ID: 10383158
[TBL] [Abstract][Full Text] [Related]
11. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S
Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746
[TBL] [Abstract][Full Text] [Related]
12. A theoretical study of some new analogues of the anti-cancer drug camptothecin.
Jena NR; Mishra PC
J Mol Model; 2007 Jan; 13(1):267-74. PubMed ID: 17024403
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship of alkyl camptothecin esters.
Cao Z; Pantazis P; Mendoza J; Early J; Kozielski A; Harris N; Vardeman D; Liehr J; Stehlin JS; Giovanella B
Ann N Y Acad Sci; 2000; 922():122-35. PubMed ID: 11193888
[TBL] [Abstract][Full Text] [Related]
14. The current status of camptothecin analogues as antitumor agents.
Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
Tsunoda T
Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938
[No Abstract] [Full Text] [Related]
16. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
17. A review of the clinical experience with irinotecan (CPT-11).
Horowitz RW; Wadler S; Wiernik PH
Am J Ther; 1997; 4(5-6):203-10. PubMed ID: 10423612
[TBL] [Abstract][Full Text] [Related]
18. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
[TBL] [Abstract][Full Text] [Related]
19. Camptothecin. Discovery to clinic.
Wall ME; Wani MC
Ann N Y Acad Sci; 1996 Dec; 803():1-12. PubMed ID: 8993495
[No Abstract] [Full Text] [Related]
20. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]